Skip to search formSkip to main contentSkip to account menu

GSK2110183

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

DiaminesPyrazolesafuresertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Regulation der NKG2D Stressliganden MICA, MICB und ULBP2 in proliferierenden und seneszenten Tumorzellen
Das maligne Melanom stellt die todlichste Form aller Hautkrebserkrankungen dar und entsteht durch eine maligne Transformation der… 
2016
2016
Abstract 1192: Preclinical evaluation of HER3 mutations and rational combinations with AKT inhibition in enhancing anti-tumor activity of HER3 inhibition in gastric cancer
Molecular activating events involving the ERBB RTK family members (EGFR (ERBB1), HER2 (ERBB2), HER3 (ERBB3), HER4 (ERBB4)) drive… 
2014
2014
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
2011
2011
Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study
Abstract 1856 Background: Despite significant progress in treatment, multiple myeloma (MM) remains an incurable disease. There is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)